Open Access

Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy

  • Authors:
    • Wei Cheng
    • Aimudula Ainiwaer
    • Lei Xiao
    • Qian Cao
    • Ge Wu
    • Ying Yang
    • Rui Mao
    • Yongxing Bao
  • View Affiliations

  • Published online on: May 4, 2015     https://doi.org/10.3892/mmr.2015.3725
  • Pages: 2451-2456
  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to determine the correlation between hepatocellular carcinoma (HCC) and heat shock protein 90 (HSP90), involved in tumor angiogenesis, and to evaluate the effect of AUY922, a HSP90 inhibitor, in HCC. The expression of HSP90 and microvessel density (MVD) were measured in tissue samples from 76 patients with HCC by immunohistochemistry. Western blot analysis was performed to detect the expression of HSP90 in the HCC tissues and different HCC cell lines. The effects of time and concentration treatment with the AUY922 HSP90 inhibitor were investigated in HepG2 cells. Cell proliferation was measured using an MTT assay and a Transwell assay was performed to evaluate the migration of the HepG2 cells following treatment with different concentrations of AUY922. Positive staining of HSP90 was observed in 88.16% (67/76) of the HCC tissues, compared with 16.67% (4/24) of the normal tissues. The difference in the expression of HSP90 between the HCC and normal tissues was statistically significant (P<0.001). Tumors exhibiting positive expression of HSP90 had significantly higher MVD compared with the HSP90‑negative counterparts (82.8±12.44 vs. 23.8±8.07, respectively; P<0.001). The expression levels of HSP90 were positively correlated with MVD in all the tissue samples (r_s=0.724; P<0.001). AUY922 inhibited the proliferation of the HepG2 cells in a time‑ and concentration‑dependent manner, and the migration of HepG2 cells was distinctly suppressed following treatment with AUY922. These data suggested that the angiogenesis of human HCC may be mediated by HSP90, and that the specific HSP90 inhibitor, AUY922, has a therapeutic role in the treatment of HCC. Therefore, HSP90 may represent a selective target in molecularly targeted treatment of HCC.
View Figures
View References

Related Articles

Journal Cover

August-2015
Volume 12 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng W, Ainiwaer A, Xiao L, Cao Q, Wu G, Yang Y, Mao R and Bao Y: Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy. Mol Med Rep 12: 2451-2456, 2015.
APA
Cheng, W., Ainiwaer, A., Xiao, L., Cao, Q., Wu, G., Yang, Y. ... Bao, Y. (2015). Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy. Molecular Medicine Reports, 12, 2451-2456. https://doi.org/10.3892/mmr.2015.3725
MLA
Cheng, W., Ainiwaer, A., Xiao, L., Cao, Q., Wu, G., Yang, Y., Mao, R., Bao, Y."Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy". Molecular Medicine Reports 12.2 (2015): 2451-2456.
Chicago
Cheng, W., Ainiwaer, A., Xiao, L., Cao, Q., Wu, G., Yang, Y., Mao, R., Bao, Y."Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy". Molecular Medicine Reports 12, no. 2 (2015): 2451-2456. https://doi.org/10.3892/mmr.2015.3725